Massimiliano Beltramo

US Patent:

6525090, Feb 25, 2003

Filed:

Apr 7, 1999

Appl. No.:

09/287598

Inventors:

Daniele Piomelli - San Diego CA
Massimiliano Beltramo - San Diego CA

Assignee:

Neurosciences Research Foundation, Inc. - San Diego CA

International Classification:

A61K 3134

US Classification:

514473, 514460

Abstract:

Methods are disclosed for treating or preventing disorders such as mental diseases, inflammation and pain by inhibiting the enzyme anandamide amidohydrolase. A therapeutically effective level of an anandamide amidohydrolase inhibitor is administered such as a therapeutically effective level of a haloenol lactone. Preferably, the haloenol lactone is of the formula: wherein R is hydrogen, R is a halogen, and R is selected from the group consisting of aryl, aryloxy, and heteroaryl radicals, derivatives of said haloenol lactones, and mixtures thereof. The haloenol lactone, E-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyrane-2-one, is most preferred.

US Patent:

20030134894, Jul 17, 2003

Filed:

Feb 20, 2003

Appl. No.:

10/369794

Inventors:

Daniele Piomelli - San Diego CA, US
Massimiliano Beltramo - San Diego CA, US

International Classification:

A61K031/366

US Classification:

514/460000

Abstract:

Methods are disclosed for treating or preventing disorders such as mental diseases, inflammation and pain by inhibiting the enzyme anandamide amidohydrolase. A therapeutically effective level of an anandamide amidohydrolase inhibitor is administered such as a therapeutically effective level of a haloenol lactone. Preferably, the haloenol lactone is of the formula: wherein R is hydrogen, Ris a halogen, and Ris selected from the group consisting of aryl, aryloxy, and heteroaryl radicals, derivatives of said haloenol lactones, and mixtures thereof. The haloenol lactone, E-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyrane-2-one, is most preferred.

US Patent:

20050113445, May 26, 2005

Filed:

Oct 19, 2004

Appl. No.:

10/967954

Inventors:

Daniele Piomelli - San Diego CA, US
Massimiliano Beltramo - San Diego CA, US

International Classification:

A61K031/366

US Classification:

514460000

Abstract:

Methods are disclosed for treating or preventing disorders such as mental diseases, inflammation and pain by inhibiting the enzyme anandamide amidohydrolase. A therapeutically effective level of an anandamide amidohydrolase inhibitor is administered such as a therapeutically effective level of a haloenol lactone. Preferably, the haloenol lactone is of the formula: wherein R is hydrogen, Ris a halogen, and Ris selected from the group consisting of aryl, aryloxy, and heteroaryl radicals, derivatives of said haloenol lactones, and mixtures thereof. The haloenol lactone, E-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyrane-2-one, is most preferred.

US Patent:

20060079574, Apr 13, 2006

Filed:

Oct 7, 2005

Appl. No.:

11/246500

Inventors:

Daniele Piomelli - San Diego CA, US
Massimiliano Beltramo - San Diego CA, US

International Classification:

A61K 31/366
A61K 31/16

US Classification:

514460000, 514625000

Abstract:

Methods are disclosed for treating or preventing disorders such as mental diseases, inflammation and pain by inhibiting the enzyme anandamide amidohydrolase. A therapeutically effective level of an anandamide amidohydrolase inhibitor is administered such as a therapeutically effective level of a haloenol lactone. Preferably, the haloenol lactone is of the formula: wherein R is hydrogen, Ris a halogen, and Ris selected from the group consisting of aryl, aryloxy, and heteroaryl radicals, derivatives of said haloenol lactones, and mixtures thereof. The haloenol lactone, E-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyrane-2-one, is most preferred.

US Patent:

20070082946, Apr 12, 2007

Filed:

Nov 17, 2006

Appl. No.:

11/602130

Inventors:

Daniele Piomelli - San Diego CA, US
Massimiliano Beltramo - San Diego CA, US

International Classification:

A61K 31/366

US Classification:

514460000

Abstract:

Methods are disclosed for treating or preventing disorders such as mental diseases, inflammation and pain by inhibiting the enzyme anandamide amidohydrolase. A therapeutically effective level of an anandamide amidohydrolase inhibitor is administered such as a therapeutically effective level of a haloenol lactone. Preferably, the haloenol lactone is of the formula: wherein R is hydrogen, Ris a halogen, and Ris selected from the group consisting of aryl, aryloxy, and heteroaryl radicals, derivatives of said haloenol lactones, and mixtures thereof. The haloenol lactone, E-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyrane-2 -one, is most preferred.

US Patent:

59256729, Jul 20, 1999

Filed:

Dec 6, 1996

Appl. No.:

8/764104

Inventors:

Daniele Piomelli - San Diego CA
Massimiliano Beltramo - San Diego CA

Assignee:

Neurosciences Research Foundation, Inc. - San Diego CA

International Classification:

A61K 3134
A61K 3135

US Classification:

514460

Abstract:

Methods are disclosed for treating or preventing disorders such as mental diseases, inflammation and pain by inhibiting the enzyme anandamide amidohydrolase. A therapeutically effective level of an anandamide amidohydrolase inhibitor is administered such as a therapeutically effective level of a haloenol lactone. Preferably, the haloenol lactone is of the formula: ##STR1## wherein R is hydrogen, R. sub. 1 is a halogen, and R. sub. 2 is selected from the group consisting of aryl, aryloxy, and heteroaryl radicals, derivatives of said haloenol lactones, and mixtures thereof. The haloenol lactone, E-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyrane-2-one, is most preferred.